Our proprietary technology leverages biomimicry and evidence-based medicine to treat patients with chronic wounds.
Location: United Kingdom, Wales, Cardiff
Employees: 11-50
Total raised: $34.16M
Founded date: 2015
Investors 2
| Date | Name | Website |
| - | Bionova Ca... | bionovacap... |
| - | Syndicate ... | syndicater... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 28.03.2023 | Series B | $13.37M | - |
| 10.08.2021 | Series A | $20.79M | - |
Mentions in press and media 13
| Date | Title | Description |
| 18.06.2025 | From Waste to Wardrobe: The Future of Sustainable Fashion | In a world grappling with climate change, the fashion industry stands at a crossroads. Traditional textile production is a resource hog, draining water and energy while contributing to pollution. But what if the solution lies in the very wa... |
| 16.06.2025 | SolasCure receives FDA Fast Track Designation for Aurase Wound Gel to treat calciphylaxis ulcers | Recognises the potential of Aurase Wound Gel to improve outcomes for individuals with calciphylaxis ulcers, a rare and life-threatening condition Represents a new indication for Aurase Wound Gel, currently in Phase II Clinical Trials for tr... |
| 28.03.2023 | Biotech startup SolasCure raises USD 13.3 million in Series B | Cambridge, UK-based biotechnology company, SolasCure raised GBP 10.9 million (USD 13.3 million) in Series B funding. The round took place on March 27, 2023. Seneca Partners led the financing for the company. Meanwhile, industry veterans, in... |
| 27.03.2023 | SolasCure announces completion of GBP 10.9m Series B investment round to advance wound care innovation | Funding will support the development of Aurase Wound Gel and progress toward further Phase II clinical trials of innovative wound debriding enzyme Cambridge, UK - SOLASCURE Ltd, a biotechnology company developing a hydrogel containing a rec... |
| 27.03.2023 | SolasCure Closes GBP 10.9M Series B Funding | SolasCure, a Cambridge, UK-based biotechnology company developing a hydrogel containing a recombinant enzyme, raised GBP 10.9M in Series B funding. The round was led by Seneca Partners with participation from BRAIN Biotech AG, EVA Pharma, J... |
| 27.05.2022 | EIT Health Catapult 2021-22 names winners | This year’s EIT Health Catapult competition crowned Ebenbuild, Leuko and SolasCure as champions at the EIT Health Summit. The Catapult competition looks to boost the development of European health start-ups by exposing them to world-class e... |
| 18.05.2022 | Cambridge biotech company earns international recognition as first trial patient receives treatment | SolasCure, a Cambridge-based biotech company developing revolutionary wound-cleaning technology, sees its first trial patient receive treatment. Leveraging biomimicry and evidence-based medicine, the pioneering biologics company is developi... |
| 06.12.2021 | 21 start-ups reach EIT Health Catapult Final | Twenty-one start-ups from across Europe have secured their places at the EIT Health Catapult Final. The finalists represent the most promising European start-ups across biotech, medtech and digital health. The EIT Health Catapult, currentl... |
| 22.10.2021 | SolasCure begins clinical trials of its investigational wound cleaning product | SolasCure begins clinical trials of its investigational wound cleaning product 22-10-2021 Cambridge-based biologics company SolasCure has received authorisation to conduct clinical trials for its investigational product, Aurase Wound Gel, f... |
| 19.08.2021 | SolasCure Raises UK£1.2M in Funding | SolasCure, a Cambridge, UK-based biotech startup, raised £1.2m in funding. Seneca Partners invested: £733k invested via Seneca EIS Portfolio Service, and £500K via Seneca Growth Capital VCT. The company intends to use the funds for the furt... |
Show more